DE69328792D1 - Behandlung von migräne - Google Patents

Behandlung von migräne

Info

Publication number
DE69328792D1
DE69328792D1 DE69328792T DE69328792T DE69328792D1 DE 69328792 D1 DE69328792 D1 DE 69328792D1 DE 69328792 T DE69328792 T DE 69328792T DE 69328792 T DE69328792 T DE 69328792T DE 69328792 D1 DE69328792 D1 DE 69328792D1
Authority
DE
Germany
Prior art keywords
migraine
blocking agent
treatment
administered
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69328792T
Other languages
English (en)
Other versions
DE69328792T2 (de
Inventor
Arthur M Goldberg
Leonard Lachman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribogene Inc
Original Assignee
Ribogene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribogene Inc filed Critical Ribogene Inc
Application granted granted Critical
Publication of DE69328792D1 publication Critical patent/DE69328792D1/de
Publication of DE69328792T2 publication Critical patent/DE69328792T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Disintegrating Or Milling (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Catalysts (AREA)
DE69328792T 1992-03-13 1993-03-08 Behandlung von migräne Expired - Fee Related DE69328792T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/850,566 US5242949A (en) 1992-03-13 1992-03-13 Treating classic migraine
PCT/US1993/002132 WO1993017672A1 (en) 1992-03-13 1993-03-08 Treatment of migraine

Publications (2)

Publication Number Publication Date
DE69328792D1 true DE69328792D1 (de) 2000-07-06
DE69328792T2 DE69328792T2 (de) 2001-02-01

Family

ID=25308498

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69328792T Expired - Fee Related DE69328792T2 (de) 1992-03-13 1993-03-08 Behandlung von migräne

Country Status (18)

Country Link
US (1) US5242949A (de)
EP (1) EP0727986B1 (de)
JP (1) JP2839207B2 (de)
KR (1) KR950701215A (de)
AT (1) ATE193441T1 (de)
AU (1) AU675931B2 (de)
CA (1) CA2131991C (de)
DE (1) DE69328792T2 (de)
DK (1) DK0727986T3 (de)
ES (1) ES2148222T3 (de)
FI (1) FI944236A (de)
GR (1) GR3034188T3 (de)
HU (1) HUT71834A (de)
MX (1) MX9301393A (de)
NO (1) NO943372L (de)
PH (1) PH30101A (de)
PT (1) PT727986E (de)
WO (1) WO1993017672A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408026A (en) * 1993-08-23 1995-04-18 Cowan; Patrick J. Curable and cured organosilicon compositions, and process for making same
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US7022342B2 (en) 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
WO2008115797A1 (en) * 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
WO2009103150A1 (en) * 2008-02-20 2009-08-27 Kevin David Smith Method for treating migraine headaches
PL2734634T3 (pl) 2011-07-22 2020-03-31 The University Of Chicago Igf-1 do zastosowania do leczenia migreny
AU2013361337A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284648A (en) * 1979-08-03 1981-08-18 The University Of Kentucky Research Foundation Nasal administration of propranolol
US4394390A (en) * 1979-08-03 1983-07-19 University Of Kentucky Research Foundation Nasal dosage forms of propranol
US4428883A (en) * 1981-03-06 1984-01-31 The University Of Kentucky Research Foundation Novel method of administering β-blockers and novel dosage forms containing same

Also Published As

Publication number Publication date
ES2148222T3 (es) 2000-10-16
PT727986E (pt) 2000-11-30
AU3799193A (en) 1993-10-05
PH30101A (en) 1996-12-27
CA2131991A1 (en) 1993-09-16
ATE193441T1 (de) 2000-06-15
FI944236A0 (fi) 1994-09-13
US5242949A (en) 1993-09-07
JPH08500329A (ja) 1996-01-16
HU9402612D0 (en) 1994-11-28
KR950701215A (ko) 1995-03-23
NO943372L (no) 1994-11-14
MX9301393A (es) 1994-08-31
NO943372D0 (no) 1994-09-12
EP0727986A1 (de) 1996-08-28
DE69328792T2 (de) 2001-02-01
EP0727986A4 (de) 1995-04-25
EP0727986B1 (de) 2000-05-31
FI944236A (fi) 1994-11-11
DK0727986T3 (da) 2000-10-30
GR3034188T3 (en) 2000-11-30
JP2839207B2 (ja) 1998-12-16
WO1993017672A1 (en) 1993-09-16
HUT71834A (en) 1996-02-28
CA2131991C (en) 1999-07-06
AU675931B2 (en) 1997-02-27

Similar Documents

Publication Publication Date Title
TW200607512A (en) Use of optically pure (S,S)-reboxetine in the manufacture of a medicament for the treatment or prevention of migraine headaches
NO941065D0 (no) Fremgangsmåte og blandinger for behandling av cerebral lammelse
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
ATE144898T1 (de) Behandlung neurodegenerativer krankheiten
DE69328792D1 (de) Behandlung von migräne
DK71387A (da) Terapeutisk middel til behandling af psoriasis
DE69834724D1 (de) Behandlung von Darm- oder Blasenentzündungen
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
SE9601395D0 (sv) New therapeutic treatment 1
DE69924979D1 (de) Behandlung von chronischen schmerzen
NO962221D0 (no) Anvendelse av dimeticon for behandling av konstipasjon
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
DK0984787T3 (da) Anvendelse af lavmolekylære hepariner til forebyggelse og behandling af hjerneødemer
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
NO984198L (no) FremgangsmÕte for behandling av aggresjon
NO984190L (no) FremgangsmÕte for behandling av insomnia
PT1304107E (pt) Utilizacao de derivados de oxazolidininas para o tratamento da psoriase
NO981020D0 (no) Transdermalt terapautisk system for silatranforbindelser
RU96114051A (ru) Способ лечения экземы у травматолого-ортопедических больных с гнойной инфекцией
RU97100712A (ru) Способ лечения заболеваний пародонта
UA50329A (uk) Спосіб лікування первинної бешихи

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee